EHang Holdings Ltd - ADR vs Mesoblast Limited — how do they compare? EHang Holdings Ltd - ADR trades at $5.79 (market cap $435.35M), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Mesoblast Limited is far larger — about 5× EHang Holdings Ltd - ADR's market cap, and Mesoblast Limited is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| EH | MESO | |
|---|---|---|
Market Cap | $435.35M | $2.16B |
Sector | Industrials | Technology |
52-Week High | $19.44 | $20.96 |
52-Week Low | $4.90 | $12.88 |
Enterprise Value | $374.58M | $2.17B |
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $5.74, up 7.69% in the last session, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, flat year-over-year, but with a significant net loss of $276 million, reflecting ongoing profitability challenges despite a high gross margin of 61.53%. Recent news highlights operational progress, including the first pilotless eVTOL flight in Central Asia, but the stock remains volatile amid sector-wide pressures.
The outlook for EH is highly speculative, with substantial execution risks and negative earnings overshadowing long-term potential in the advanced air mobility market. Analyst sentiment is divided, with a consensus price target of $6.97 offering limited upside, while institutional ownership trends and cash flow volatility underscore the high-risk nature of the investment.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Trailing returns across standard periods
Latest headlines on both assets
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →